Detection bias may explain raised bladder CA risk in T2DM

Detection bias may explain raised bladder CA risk in T2DM
Early detection bias may explain the pattern of increased bladder cancer risk previously reported in patients with type 2 diabetes, according to a study published online Aug. 29 in Diabetes Care.

(HealthDay)—Early detection bias may explain the pattern of increased bladder cancer risk previously reported in patients with type 2 diabetes, according to a study published online Aug. 29 in Diabetes Care.

Isabelle N. Colmers, from the University of Alberta in Edmonton, Canada, and colleagues used linked administrative databases (1996 to 2006) to create a cohort of 185,100 adults from British Columbia, Canada, with incident , who were age-, sex-, and index date-matched to individuals without in a 1:1 ratio. During annual time windows following the index date, the incidence rates and hazard ratios for bladder cancer were calculated.

During a median follow-up of four years, the researchers found that within the study population (54 percent men; average age, 60.7 years) 1,171 new bladder cancer cases were diagnosed. Bladder cancer incidence in the diabetes cohort was 85.3 per 100,000 person-years in the first year after diabetes diagnosis, compared with 66.1 in the control cohort (adjusted hazard ratio, 1.30; P = 0.03). The increased bladder cancer risk seen in the first year was limited to those with the fewest physician visits two years prior to the index date (?12 visits, adjusted hazard ratio, 2.14; P = 0.003). Type 2 diabetes was not associated with bladder cancer after the first year.

"The results suggest that early detection bias may account for an overestimation in previously reported increased risks of associated with type 2 diabetes," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Some diabetes drugs may increase risk of bladder cancer

Jul 03, 2012

An increased risk of bladder cancer is linked to the use of pioglitazone, a medication commonly used to treat type 2 diabetes, according to a new study published in CMAJ (Canadian Medical Association Journal).

Leukocyte telomere length linked to diabetes risk

Aug 23, 2013

(HealthDay)—For American Indians, leukocyte telomere length is associated with the risk of incident diabetes, with an almost two-fold increased risk for those with the shortest versus the longest length, ...

Recommended for you

Scientist finds clearer obesity, diabetes connection

Aug 27, 2014

(Medical Xpress)—New findings about the biological links between obesity and insulin resistance and Type 2 diabetes may also shed light on the connection between obesity and cancer, says a scientist at ...

New test helps diagnose type 1 diabetes

Aug 21, 2014

(HealthDay)—The U.S. Food and Drug Administration has approved a new test that may help doctors diagnose type 1 diabetes, the most common form diagnosed in children and adolescents.

User comments